# A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-2)

> **NCT04659161** · PHASE3 · COMPLETED · sponsor: **Karuna Therapeutics, Inc., a Bristol Myers Squibb company** · enrollment: 252 (actual)

## Conditions studied

- Schizophrenia
- Schizophrenia; Psychosis

## Interventions

- **DRUG:** Xanomeline and Trospium Chloride Capsules
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04659161
- **Lead sponsor:** Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-16
- **Primary completion:** 2022-05-24
- **Final completion:** 2022-05-24
- **Target enrollment:** 252 (ACTUAL)
- **Last updated:** 2023-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04659161

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04659161, "A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-2)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04659161. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*